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Abstract
Background: Transient Receptor Potential Canonical 1 (TRPC1) is a widely-expressed mammalian cationic channel
with functional effects that include stimulation of cardiovascular remodelling. The initial aim of this study was to
investigate variation in TRPC1-encoding gene transcripts.
Results: Extensive TRPC1 transcript alternative splicing was observed, with exons 2, 3 and 5-9 frequently omitted,
leading to variants containing premature termination codons. Consistent with the predicted sensitivity of such
variants to nonsense-mediated decay (NMD) the variants were increased by cycloheximide. However it was notable
that control of the variants by NMD was prominent in human embryonic kidney 293 cells but not human vascular
smooth muscle cells. The cellular difference was attributed in part to a critical protein in NMD, up-frameshift-1
(UPF1), which was found to have low abundance in the vascular cells. Rescue of UPF1 by expression of exogenous
UPF1 was found to suppress vascular smooth muscle cell proliferation.
Conclusions: The data suggest: (i) extensive NMD-sensitive transcripts of TRPC1; (ii) inefficient clearance of aberrant
transcripts and enhanced proliferation of vascular smooth muscle cells in part because of low UPF1 expression.
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1. Background
Most mammalian orthologues of the Drosophila melano-
gaster Transient Receptor Potential (TRP) channel are
involved in regulated transmembrane Ca2+ fluxes either
because they are directly permeable to Ca2+ or because
they are permeable to Na+ and therefore indirectly affect
intracellular Ca2+ [1,2]. TRPC1 was the first of the mam-
malian TRP channels to be cloned and has been found to
be widely expressed throughout the body [3-5]. There is
general agreement that it contributes to Ca2+ and Na+
entry but it should be appreciated that its functions often
depend on heteromultimerisation with other TRP pro-
teins or regulators [3,6]. TRPC1 and its associated TRPC
channels are not voltage-gated ion channels but relatively
slow chemically-modulated channels. Activation by
depletion of Ca2+ stores has been described but there is
also stimulation by agonists of G protein-coupled recep-
tors, oxidized phospholipids [3,7-9] and redox factors
[10]. Important functions of TRPC1 have been indicated
in many mammalian systems, including in cell hypertro-
phy, migration and proliferation [3,4,11]. In the cardio-
vascular system TRPC1 stimulates vascular smooth
muscle cell (VSMC) hypertrophy and hyperplasia [12-14]
as well as cardiac hypertrophy evoked by aortic constric-
tion [11]. Furthermore, it is up-regulated in response to
vascular injury [12] and metabolic syndrome [15] and
down-regulated by exercise [15], consistent with it play-
ing important roles in pathological cardiovascular
remodelling.
Relatively little is known about the control of TRPC1
gene expression other than that there is regulation by
NFB, HIF-1 and Ca2+ [16-18]. Splice variation of
TRPC1 transcripts has been reported but there has been
little investigation of the topic and so the extent and
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importance are unknown. One variant corresponded to
13 exons but other variants lacked one or both of exon 2
and exon 3, and thus contained only 11 or 12 exons
[5,19,20]. Other variants, some with additional exonic
sequences, have been suggested [21].
Nonsense-mediated decay (NMD) is a major RNA
surveillance mechanism, degrading mRNAs that contain
premature termination codons (PTCs) in eukaryotic
cells [22-25]. Increasingly NMD is suggested to play
roles in suppressing human diseases [22,26]. The first
step in NMD involves attachment of an exon-junction
complex 5’ of exon-exon junctions during splicing in
the nucleus. If mRNA lacks PTCs, exon-junction com-
plexes are stripped during the first round of translation
by the ribosome. However, the exon-junction complex
recruits NMD factors if PTCs are detected at least 50
nucleotides upstream of the final exon-exon junction.
Decapping and degradation of such transcripts then fol-
lows. A key NMD factor is the phosphoprotein up-fra-
meshift-1 (UPF1, or RENT1). Decay of PTC-containing
RNAs occurs when UPF1 interacts with UPF2 and UPF3
[23]. Although originally thought only to be a system for
degrading aberrantly spliced transcripts, NMD and alter-
native splicing can couple together in a process termed
regulated unproductive splicing and translation [27,28].
NMD has been suggested to be important in genetic
cardiomyopathies [29] but, to the best of our knowledge,
there is no information on the relevance to TRP chan-
nels, VSMCs, or vascular remodelling.
In this study we made a survey of splicing in human
TRPC1 gene transcripts and investigated the potential
relevance. The investigation primarily focused on prolif-
erating human saphenous vein VSMCs obtained during
coronary artery bypass graft surgery. Hyperplasia in
these VSMCs is a key determinant of long-term failure
of saphenous vein bypass grafts [12-14]. Human brain
and aorta mRNA libraries and human embryonic kidney
(HEK) 293 cells were used for comparison.
2. Results
2.1 Multiple TRPC1 transcripts containing premature
termination codons (PTCs)
A segmental RT-PCR scan was performed based on the
predicted exonic structure of TRPC1 gene using human
brain mRNA as a template. PCR primers spanning from
exon 1 to 5 most noticeably amplified transcript lacking
exon 3 (Figure 1a). A smaller product lacking exons 2
and 3 was also evident (Figure 1a). Primers spanning
exon 6 to 10 revealed products lacking exons 8 and 9,
or 9 alone (Figure 1b). In contrast, exon 9-13 PCR
revealed only one full-length product, indicating absence
of alternative splicing in this segment (Figure 1c).
Parallel reactions performed in the absence of reverse
transcriptase yielded no products, confirming that bands
shown in Figure 1 arose from mRNA (the data are not
shown but see below). For each primer pair, PCR was
also performed using recombinant TRPC1 cDNA clone
as a template control. The clone contained exons 1-2
and 4-13, and no intronic structure. PCR reactions on
the clone revealed only single products, showing that
the additional products from mRNA did not arise
because of mis-priming on a single TRPC1 template
(Figure 1a-c).
More detailed investigation was performed by using
PCR primers spanning from exon 1 to exon 10 followed
by sub-cloning and DNA sequencing of PCR products.
Full-length transcript was evident but there were also
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Figure 1 Segmental RT-PCR scan of TRPC1 mRNA species. (a-c)
PCR on reverse-transcribed human brain mRNA (’mRNA’) and the
cloned human Δ3 TRPC1 cDNA (’clone’). As indicated by the exon
schematics below each gel, PCR primers (forward and reverse
arrows) spanned from exons 1 to 5 (a), 6 to 10 (b), or 9 to 13 (c).
ORF: open reading frame. (d) Example raw data from PCR primers
spanning from exon 1 to exon 10. Sequencing showed that the
upper band was full-length sequence except for exon 3 (Δ3) and
that the lower band lacked exons 2, 3 and 5-9 (Δ 2,3,5-9). (a-d)
Experiments were repeated independently 4 times and yielded
similar results.
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smaller products. An example of the gel analysis is
shown for human brain mRNA (Figure 1d). The
approach was also applied to mRNA from HEK 293
cells, human saphenous vein, and human aorta. In each
case, reactions of the type shown in Figure 1d were
investigated by sub-cloning and sequencing to provide
insight into the scope and characteristics of the splice
variants. The experiments showed that multiple novel
TRPC1 transcripts could be detected, including dele-
tions of exons 2-3 and 5-9 (Figures 2 &3). Frame-shift
and premature termination codon (PTC) insertion in
exon 4 was observed to occur through deletion of exons
2 and 3 (Figure 2a). In one clone, a novel 98-bp exon
(exon 3a) was observed with exon hallmarks ending in
the CAG nucleotide sequence and having exon bound-
aries delineated by intronic AG acceptor and GC donor
sites (Figure 2b). Although inclusion of exon 3a con-
ferred a PTC it was made redundant by prior deletion
of exon 2, resulting in a frame-shift in exon 3.
We did not attempt to define all splice variants or pro-
vide statistical analysis of the frequency of each variant but
the data sample summarised in Figure 3a supports the
conclusion that there is extensive splicing in TRPC1
transcripts. Out of the variants analysed, exons 2, 3 and 5-
9 were omitted cassette exons whereas exon 4 was always
present and thus constitutively spliced (Figure 3a). Tran-
scripts contained frame-shifts that led to PTCs in or
before exon 10 except in one case from human aorta
where there was an in-frame deletion of 255 bp corre-
sponding to the last half of exon 7 (Figure 3a). In Figure
3b the exons are aligned approximately with the six pre-
dicted transmembrane segments (S1-S6) and ion pore
region (P) of the TRPC1 protein, showing that the inser-
tion of PTCs will affect the transmembrane integrity and
ion pore of the TRPC1 protein. Overall, the data suggest
that PTC-containing variants are varied and complex,
including in human blood vessels, and that they are likely
to have negative effects on the generation and function of
TRPC1 protein.
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Figure 2 Novel TRPC1 transcripts. (a) Example TRPC1 splice
variant in human brain: skipping of exons 2 and 3 causes a frame-
shift and a PTC in exon 4 (bold, underlined). (b) Novel TRPC1 exon
between exons 3 and 4 in human aorta. Exon-boundary donator
and acceptor sites are marked.
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Figure 3 Summary of sequenced TRPC1 transcripts. (a) Results
from long PCR and TOPO sub-cloning followed by direct DNA
sequencing. Messenger RNA was from HEK 293 cells (i), human brain
(ii), human saphenous vein (iii), and human aorta (iv). The numbers in
the boxes indicate the exon numbers (5’-3’, left to right). # indicates
the Δ8,9 transcript studied in the functional assays of Figure 6. Grey
shading indicates open reading frames (i.e. all but one shows a PTC).
(b) Schematic showing the relationship between 13 primary exons of
the transcript (tr) and the TRPC1 protein (pr) from amino (N) to
carboxy (C) terminus and showing the transmembrane-spanning
segments (S1-S6) and the ion pore region (P).
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2.2 Cell type-dependent nonsense-mediated decay (NMD):
low efficiency at TRPC1 transcripts in VSMCs
Because NMD depends on first round translation it is
acutely sensitive to cycloheximide, which inhibits pepti-
dyl transferase activity of the 60S ribosomal subunit
[30]. Therefore, to investigate the relevance of NMD,
TRPC1 transcripts were investigated in cells after 6 hr
treatment with cycloheximide or vehicle control using
PCR primer pairs spanning from exon 6 to 10. In HEK
293 cells, cycloheximide increased the abundance of
TRPC1 transcripts that had deletions of exons 8 and 9
(TRPC1 Δ8,9) (Figure 4a) or deletion of exons 2, 3 and
5-9 (data not shown). Cycloheximide had no effect on
the abundance of the ‘house-keeper’ mRNA that
encoded b-actin (Figure 4a). In contrast, in human
saphenous vein VSMCs cycloheximide had no effect on
TRPC1 transcripts (Figure 4b). Moreover, under basal
conditions (i.e. in the absence of cycloheximide) the
abundance of the TRPC1 Δ8,9 variant was apparently
greater in VSMCs compared with HEK 293 cells (Figure
4bcf Figure 4a). This difference was also detected when
comparing HEK 293 cell mRNA with mRNA from
human aorta or human saphenous vein (Figure 4c).
Efforts were made to develop intra-exon PCR pri-
mers to enable real-time PCR quantification of exon
expression. Unfortunately, because of the small size of
the exons, we were only successful with intra-exon 4
primers, which target a constitutively spliced exon that
was not different between samples (data not shown).
We also note that the data of Figure 4a-c revealed
PCR products in addition to those identified as Δ9 or
Δ8,9 and which are unmarked in the figure panels.
The sequences of these products were not determined.
The abundance of these other PCR products may have
decreased with increasing abundance of the Δ8,9 var-
iant (Figure 4a) because they were out-competed in
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Figure 4 Differential nonsense-mediated decay (NMD) of TRPC1 transcripts. (a, b) In paired experiments, cells were pretreated with vehicle
control (dimethylsulphoxide) or 25 μg/ml cycloheximide (CHX) for 6 hr prior to isolation of RNA and reverse transcription. PCR primer pairs
spanned from exon 6 to 10 and data are shown with (+) and without (-) reverse transcriptase (RT) reaction. (a) HEK 293 cell data. The lower
panel shows analysis of b-actin mRNA expression in the same samples. (b) Human saphenous vein VSMC data. (c) PCR with primers spanning
exons 6 to 10. (a, c) Messenger RNA was analysed with (+) or without (-) reverse transcription (RT). (a-c) Experiments were repeated
independently 4 times and yielded similar results.
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the multiple PCR reactions occurring within the single
tube.
The data are consistent with the degradation of PTC-
containing TRPC1 variants via the NMD pathway in
HEK 293 cells but absence (or low efficiency) of such a
mechanism in VSMCs.
2.3 Low UPF1 in VSMCs
A possible explanation for the absence or inefficiency of
NMD in the VSMCs is paucity of a key component of the
NMD machinery such as UPF proteins. Analysis of mRNA
species encoding up-frameshift (UPF) proteins revealed
clear expression of UPF1, UPF2 and UPF3B in HEK 293
cells (Figure 5a-c). In contrast in VSMCs, mRNAs encod-
ing UPF2 and UPF3B were readily detected but mRNA
encoding UPF1 was difficult to detect (Figure 5a-c). The
example experiment indicates a small amount of UPF1
mRNA (Figure 5a) but quantitative real-time PCR mea-
surement was not possible because the mRNA species was
undetectable in most samples (Figure 5d).
Protein abundance may be preserved by low protein
turn-over in the face of low mRNA expression. There-
fore, UPF1 protein was analysed by western blotting.
Anti-UPF1 antibody labelled protein of the expected
mass for UPF1, 123 kDa (Figure 5e). Two other anti-
UPF1 antibodies labelled protein of the same size (data
not shown). To determine UPF1 abundance, equal
amounts of total protein were loaded from HEK 293
and VSMC lysates. Although UPF1 was evident in
VSMCs, its abundance was 3.1 times less compared
with HEK 293 cells (Figure 5e, f).
The data suggest that VSMCs have very low mRNA
and relatively low protein abundance of UPF1, a critical
component of the NMD mechanism.
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Figure 5 Expression of UPFs 1-3. (a-c) Example gels showing expression of mRNAs encoding UPF1 (a), UPF2 (b) and UPF3B (c) in HEK 293 and
human saphenous vein VSMCs. Data are shown with (+) or without (-) reverse transcriptase (RT) reaction. (d) Mean data showing abundance of
UPF1-3 mRNA species relative to b-actin in HEK 293 cells and VSMCs. (e) For a representative experiment, detection of UPF1 protein in HEK 293
cells and VSMCs. UPF1 was detected close to the expected molecular mass of 123 kDa. (f) Mean normalized data for experiments of the type
illustrated in (e) (n = 3).
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2.4 Effect of UPF1 rescue on VSMC proliferation
Previous studies have suggested that NMD is important
as a suppressor of human diseases [22,26]. Coronary
artery bypass grafts are carried out because individuals
have coronary artery disease. The saphenous veins of
these patients are prone to neointimal hyperplasia.
Therefore, we hypothesised that a net effect of low
UPF1 abundance may be to enhance proliferation of
saphenous vein VSMCs. VSMCs were compared after
transfection with control vector or vector expressing
human UPF1 to rescue UPF1 levels. UPF1 suppressed
VSMC proliferation (Figure 6).
The data suggest that low UPF1 and NMD in VSMCs
stimulate cell proliferation and that the effect can be
protected against by expression of exogenous UPF1.
2.5 Function of TRPC1 Δ8,9
Protein encoded by the Δ8,9 deletion is predicted to
comprise only the first two membrane-spanning seg-
ments of TRPC1 (see Figure 3b). The variant is suscepti-
ble to NMD in HEK 293 cells where it has low
abundance (Figure 4a, c), but in VSMCs (where NMD is
inefficient) there is significant mRNA encoding the var-
iant (Figure 4b, c). To investigate if the variant has cap-
ability to be functional we generated it in a mammalian
expression vector and transfected HEK 293 cells because
these cells have low endogenous expression of the var-
iant. Because TRPC1 is associated with Ca2+ entry, the
amplitude of Ca2+-entry was investigated in two paired
sets of experiments: one comparing DNA vector with
vector expressing the Δ8,9 variant; and the other com-
paring the DNA vector with vector expressing wild-type
TRPC1. It was observed that the Δ8,9 variant partly
inhibited Ca2+ entry where as wild-type TRPC1
increased it (Figure 7).
The data suggest that short TRPC1 variants (such as
Δ8,9) have an effect on Ca2+-entry that is opposite to
that of wild-type TRPC1, causing inhibition.
3. Discussion
The data add to existing knowledge of alternative spli-
cing in TRPC1 transcripts, showing that the splicing is
extensive and commonly leads to frame-shifts with
PTCs. These PTC variants are susceptible to NMD and
may have no functional consequence unless NMD is
compromised. Intriguingly, compromised NMD has pre-
viously been suggested in disease conditions and we
observed weak or non-existent NMD in VSMCs from
patients with coronary artery disease. Furthermore, we
were able to show that weak NMD was associated with
low expression of UPF1, a key protein of the NMD
machinery. Therefore, although aberrant TRPC1 tran-
scripts presumably reflect only a tiny fraction of the
total aberrant variants of all genes in the cells, study of
TRPC1 has led us to investigation of NMD and UPF1 in
the vasculature and the first suggestion that they are
relevant to unwanted vascular remodelling.
There is relatively little prior evidence that expression
of UPF1 varies across cell types or changes in disease.
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numbers for 4 independent paired experiments on cells from 4
patients (labelled 1, 2, 3, 4), each comparing the effect of
transfection with the vector and transfection with vector expressing
human UPF1. Data from the 4 patients were combined (labelled
‘all’) for statistical analysis.
125
*
100
*
on
se )
75re
sp
o
on
tr
ol
50-b
ac
k 
ct
or
 c
o
25+  a
dd
-
(%
 v
ec
0
or orC1 C1
C
a2
(
ve
ct
ve
ct
9 T
RP
wt
 TR
P
'8,
Figure 7 Inhibition of Ca2+ entry by over-expressed TRPC1
Δ8,9 in HEK 293 cells. Measurement of the intracellular Ca2+
concentration in transfected cells pretreated with 1 μM thapsigargin
in zero Ca2+ solution before addition of 1.5 mM Ca2+ as indicated.
Mean peak responses to 1.5 mM Ca2+ are shown for paired
experiments, one comparing vector (n/N = 11/39) with vector
containing the TRPC1-Δ8,9 insert (n/N = 13/35), the other
comparing vector (n/N = 3/60) with vector containing full-length
(FL) TRPC1 without the Δ8,9 deletion (n/N = 3/45). Test data are
normalised to their respective controls (vector only).
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Higher Upf1 mRNA abundance was detected in mouse
testis but no differential expression was detected across
a range of other physiological murine tissues [31]. Varia-
tion in expression of other NMD components occurred
however, and up to 2-fold difference in NMD efficiency
was suggested [31]. UPF1 is also a phosphoprotein and
so its activity, rather than expression, may be a source
of variation [23,24]. Stress factors such as reactive oxy-
gen species may also inhibit NMD [32]. Nevertheless, as
far as we are aware, our data provide the first evidence
for markedly lower UPF1 mRNA and relatively low
UPF1 protein in a cell or tissue type. Our data suggest
that efficient NMD requires a certain abundance of
UPF1 because the protein was not completely absent
from VSMCs. It may be important that UPF1 was not
completely absent because knock-out of the mouse gene
(Upf1) is embryonically lethal [33] and strong knock-
down of UPF1 arrests HELA cells in S phase [34]. It
would, therefore, seem that mammalian cells require
UPF1/Upf1. The origin and condition of the vein and
VSMCs used in our experiments may have been influen-
tial because the cells of these veins will have been under
stress in the patient and are particularly prone to prolif-
erative and migratory behaviour, which is why there is a
significant problem with subsequent neointimal hyper-
plasia [12,35]. Our data suggest that a previously unrec-
ognised contributory factor in the aberrant proliferative
behaviour may be compromised NMD due, at least in
part, to low UPF1 expression. Consistent with this
hypothesis, we were able to show that elevation (i.e. res-
cue) of UPF1 suppressed proliferation in VSMCs.
Short, N-terminal, variants of other TRP channel
types have been described, including for TRPC2 [36],
TRPC4 [37], TRPM1 [38] and TRPM2 [39]. Each var-
iant is inhibitory for Ca2+-entry, as we describe for the
Δ8,9 (N-terminal) variant of TRPC1. Therefore, it may
be a common theme in TRP channels that there are
inhibitory N-terminal variants that are variably
expressed depending on activities of the spliceosome
and NMD. However, it should be noted that although
we showed native expression of Δ8,9 mRNA and other
PTC-containing variants, we did not show that the var-
iants led to proteins. Detection of endogenous ion chan-
nel proteins is notoriously difficult and the difficulty
increases with splice variants that have even lower
abundance. Few studies provide convincing evidence for
native expression of such variants but instead show
effects of heterologously over-expressed constructs.
With a view to detecting endogenous variants we gener-
ated an anti-TRPC1 antibody targeted to amino acid
sequence encoded by exon 1 (A Dedman & DJ Beech,
unpublished data). Unfortunately, the antibody recog-
nised over-expressed TRPC1 but lacked sufficient speci-
ficity to definitively identify short forms of endogenous
TRPC1. Therefore, we cannot be sure that such short
TRPC1 proteins exist in VSMCs even though we know
the NMD mechanism is inefficient at TRPC1 transcripts
and the mRNA species are present. If short TRPC1 pro-
teins do exist endogenously they would be expected to
suppress TRPC1-dependent Ca2+ entry and conse-
quently also VSMC proliferation [14]. This prediction
may seem at odds with the observation that UPF1 sup-
pressed cell proliferation (Figure 6). Nevertheless, it
should be appreciated that consideration of UPF1 and
NMD only in relation to TRPC1 would be unjustifiably
restrictive; many aberrant splice variants are removed
by NMD and it is the collective effect that will deter-
mine the net consequence on cell proliferation.
Conclusions
The first half of this study identified extensive alterna-
tive splicing of TRPC1 transcripts that results in PTC-
containing variants which are susceptible to NMD.
These observations led us to find that NMD is weak or
absent in proliferating VSMCs. Our data suggest that
the weak NMD arises because of down-regulated
expression of UPF1 and that rescue of UPF1 suppresses
VSMC proliferation, a primary factor in the neointimal
hyperplasia that leads to failure of veins as bypass grafts.
We therefore suggest that inefficient NMD and down-
regulated UPF1 are previously unrecognised features of
human VSMC remodelling that result in unwanted tran-
scripts with adverse effects. The findings support and
expand previous suggestions that NMD plays a role in
suppressing human diseases [22,26].
4. Methods
4.1 Saphenous vein and cell culture
Freshly discarded human saphenous vein segments were
obtained anonymously and with informed consent from
patients undergoing open heart surgery in the General
Infirmary at Leeds. Approval was granted by the Leeds
Teaching Hospitals Local Research Ethics Committee.
The investigation conforms to principles outlined in the
Declaration of Helsinki. Transfer of vein to the laboratory
occurred in chilled Dulbecco’s Modified Eagle’s Medium
(DMEM) and the processing of the vein for experiments
occurred within 30-60 min after removal of the vein from
the patient. VSMCs were prepared using an explant tech-
nique and grown in DMEM supplemented with 10% fetal
calf serum (FCS), penicillin/streptomycin and L-gluta-
mine at 37°C in a 5% CO2 incubator. Experiments were
performed on cells passaged 2-5 times. Staining of cells
positively for smooth muscle a-actin and smooth mus-
cle-myosin heavy chain confirmed VSMC identity. HEK
293 cells were grown in Dulbecco’s modified Eagle’s
medium-F12 media (Invitrogen) supplemented with 10%
fetal bovine serum and penicillin (50 units/ml) and
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streptomycin (0.5 mg/ml) at 37°C in a 5% CO2 incubator.
For cycloheximide (CHX) treatment, cells were grown to
60% confluency and treated with 25 μg/ml CHX or the
vehicle control (dimethylsulphoxide) for 6 hr. Cells were
washed with PBS before harvesting RNA.
4.2 RNA isolation and RT-PCR
Saphenous vein was placed in Hanks’ solution (in mM:
NaCl 137, KCl 5.4, CaCl2 0.01, NaH2PO4 0.34, K2HPO4
0.44, D-glucose 8, and HEPES 5), the medial layer dis-
sected and snap-frozen immediately. Human brain total
RNA and human aorta total RNA were purchased from
Ambion (Huntingdon, UK). Messenger RNA was isolated
using TRI-reagent (Sigma) and subjected to DNase I
digestion (Ambion); 1-3 μg was reverse transcribed using
oligo dT(15) or a TRPC1 gene specific primer with AMV-
RT (Promega) or Transcriptor (Roche). Omitting reverse
transcriptase controlled for the presence of genomic DNA.
Thermal cycling was 95°C (5 min), 35 cycles (unless indi-
cated) at 94°C (30 s), 55°C (45 s), and 72°C (2 min). PCR
product (5 μl) was mixed with 1 μl loading buffer (Pro-
mega, UK) and resolved alongside appropriate DNA mar-
kers on 2% agarose-TAE gel containing ethidium bromide.
Gels were deliberately loaded heavily with PCR product in
order to reveal the lower abundance splice products.
Therefore, high abundance products appear over-loaded.
Bands were excised from gels and directly sequenced
(Lark Technologies, Essex) or PCR products were sub-
cloned using the TOPO TA system (Invitrogen) and
resulting colonies sequenced using gene-specific or M13
primers.
4.3 Real-time quantitative PCR
Real-time RT-PCR cDNA was quantified using the Roche
Lightcycler II system and LightCycler FastStart DNA Mas-
ter SYBR Green I (Roche). The total RNA input into each
reaction was constant. Total RNA abundance was quanti-
fied by Ribogreen assays (Invitrogen) using the fluorimeter
function of the Lightcycler. DNA was amplified using the
following protocol: hot-start at 95°C (10 min); 30 cycles of
95°C (10 s), 55°C (6 s) and 72°C (14-16 s). As previously
described [40], PCR crossing points (Cp) were determined
using fit-points methodology (Light-cycler software 3.5)
and RNA relative abundance calculated using 2Cp (TRPC1)/
2Cp (b-actin). Cp values for b-actin were 15.7 ± 0.16 (HEK
293 cells) and 18.0 ± 0.13 (VSMCs). As appropriate, there
was adherence to published guidelines for quantitative
RT-PCR [41].
4.4 PCR primers
TRPC1 gene-specific RT primer (5’-3’): GTTAACCT-
GACTGTGTTGACAT. TRPC1 exon 1 forward primer:
TCCATCCTCTTCCTCGC. TRPC1 exon 6 forward pri-
mer (5’-3’): ATTTAAGTCGTCTAAAACTTGCT. TRPC1
exon 5 reverse primer (5’-3’): AGCACTAAGTT-
CAAATGCT. TRPC1 exon 10 reverse primer (5’-3’):
AGAAGAAACATCCCAAGAAAT. b-actin primers (5’-
3’): ATGGATGATGATATCGCC (forward); CAAGAA
AGGTGTAACGCAAC (reverse). TRPC1 intra exon 4 pri-
mers (5’-3’): AGCTGCTCATCGTAACA (forward);
CCGGAGGCTATCCTTT (reverse). UPF1 primers (5’-3’):
TTGACAGGATGCAGAGC (forward); GGCATAAACC
TGGGAGT (reverse). UPF2 primers (5’-3’): AATGCTGA
TCGGGAGT (forward); TGTAGAATGCGCCTGT
(reverse). UPF3B primers (5’-3’): CAACCTATGCCT-
GAGC (forward); ATCGATAGTCCCGACTT (reverse).
4.5 Western blotting
Confluent monolayers of VSMCs and HEK 293 cells were
harvested in Lysis buffer (50 mM Tris, pH 8.0, 150 mM
NaCl, 2 mM EGTA, 5% glycerol, 1% Triton X-100) con-
taining protease inhibitors (Roche). For detection of
UPF1, cell lysates were cleared by 5 min centrifugation at
8000 × g and protein concentration in the supernatants
estimated by the BioRad DC protein assay. Equal
amounts of protein (13 μg) were loaded and resolved by
gel electrophoresis, transferred to nitrocellulose mem-
brane, blocked with 5% milk in 150 mM NaCl, 20 mM
Tris, pH 7.5, 0.1% Tween-20 and incubated (overnight at
4°C) with an antibody against human UPF1 (1:200) [42].
HRP-conjugated goat anti-rabbit secondary antibody
(Sigma, 1:5000, 1 hr at room temperature) and Super-
Signal PicoWest substrate (Pierce) were used for detec-
tion. Blots were also probed with an antibody against
b-actin (Santa Cruz Biotechnology, 1:1000, overnight at
4°C) followed by HRP-conjugated bovine anti-mouse
antibodies (Santa Cruz Biotechnology, 1:10,000, 1 hr at
room temperature), but b-actin was found to be differen-
tially expressed between HEK 293 cells and VSMCs.
Normalisation of UPF1 abundance relative to b-actin
yield a qualitatively similar result to that obtained by nor-
malizing to total protein (these comparative data are not
shown). Expression of UPF1 protein was also confirmed
using anti-RENT1 antibody (Santa Cruz Biotechnology)
and an antibody against human UPF1 (a gift from J.
Lykke-Andersen, University of Colorado, USA).
4.6 Generation of Δ8,9 TRPC1
TRPC1-Δ8,9 (deletion of exons 8 and 9) was engineered
by deletion PCR using as the template human TRPC1
(exon 3 deletion) in pIRES-EYFP (Clontech) and a primer
pair designed to anneal to the 3’ end of exon 7 and the 5’
end of exon 10: TATTCTGTGGATTATTGATTT-
CAATGGGACAGATG (forward) and TCTGTCCCATT-
GAAATCAATAATCCACAGAATAAG (reverse). PCR
conditions were 95°C (30 sec), then for 18 cycles, 95°C (30
sec), 55°C (1 min) and 68°C (16 min). The resulting con-
struct was sequenced to confirm identity.
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4.7 Ca2+ imaging
Cells were transfected with hTRPC1-pIRES EYFP or
hTRPC1Δ8,9-pIRES EYFP (3 μg) using lipofectamine
2000 (Invitrogen). Cells were split onto coverslips, and
used for experiments 48-72 hr later. Cells were pre-incu-
bated with 1 μM of fura PE3-AM (Calbiochem) at 37°C
for 1 hr in standard bath solution (SBS, mM: NaCl 130,
KCl 5, D-glucose 8, Hepes 10, MgCl2 1.2, CaCl2 1.5: pH
7.4 with NaOH), followed by 30 min wash period in SBS
containing 1 μM thapsigargin. Recordings were made
alternately from test and control cells. Fluorescence was
observed with an inverted microscope (Zeiss, Germany),
and a xenon arc lamp provided excitation light, the wave-
length of which was selected by a monochromator (Till
Photonics, Germany). Experiments were performed at
room temperature and emission was collected via a 510-
nm filter and sampled by a CCD camera (Orca ER;
Hamamatsu, Japan). Images were sampled every 10 s at
345 and 380 nm and analysed off-line using regions of
interest to select individual cells. [Ca2+]i is expressed as
the ratio of the emission intensities for 345 and 380 nm
(R345/380). Imaging was controlled by Openlab software
(Image Processing &Vision Company Ltd, UK).
4.8 Cell proliferation and transfection with hUPF1 cDNA
VSMCs from human saphenous vein were transfected
with cDNA encoding human UPF1 (accession number
U59323.1) or control vector using the basic Amaxa proto-
col for primary smooth muscle cells (Lonza). Briefly, cells
from confluent T75 flasks (passage 3-4) were released by
detachin (Gelantis Inc. USA), pelleted and resuspended in
Basic Nucleofector solution (Lonza). Equal numbers of
cells from each patient were transfected with 2 μg/100 μl
of hUPF1 in pCI-neo HA vector or empty vector using
Amaxa electroporation system. Cells were plated onto 6-
well plates with pre-warmed medium. After 2 days in
DMEM supplemented with 10% FCS, cells were washed
and harvested in detachin. Viable cells were identified by
trypan blue exclusion and randomised samples were
counted in a blinded fashion to assess proliferation. VSMC
samples derived from 4 patients were used in the experi-
ment and for each sample the effect on proliferation was
determined from the ratio between number of cells that
had been transfected with UPF1 and the control DNA.
4.9 Data analysis
Mean data are shown as mean ± s.e.mean. Statistical
comparisons were made using Student’s t-test between
pairs of test and control data, where statistically signifi-
cant difference is indicated by P < 0.05 (*). RT-PCR
experiments were each repeated independently at least 4
times and yielded similar data; representative experi-
ments are shown. For human vein experiments, similar
results were achieved for at least 3 independent patient
samples. For Ca2+-imaging, n is the number of indepen-
dent experiments (coverslips) and N is the number of
cells analysed per coverslip.
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